Jane Street’s Lyell Immunopharma LYEL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$646K Sell
46,011
-17,882
-28% -$324K ﹤0.01% 7450
2026
Q1
$1.28M Buy
63,893
+51,484
+415% +$1.2M ﹤0.01% 5969
2025
Q4
$382K Buy
+12,409
New +$278K ﹤0.01% 8299
2025
Q2
Sell
-3,212
Closed -$34.6K 10365
2025
Q1
$34.6K Sell
3,212
-8,760
-73% -$107K ﹤0.01% 9072
2024
Q4
$153K Sell
11,972
-2,414
-17% -$47.9K ﹤0.01% 8574
2024
Q3
$397K Buy
14,386
+5,596
+64% +$164K ﹤0.01% 7575
2024
Q2
$255K Sell
8,790
-572
-6% -$27.2K ﹤0.01% 8041
2024
Q1
$418K Sell
9,362
-5,841
-38% -$250K ﹤0.01% 7009
2023
Q4
$590K Buy
15,203
+14,465
+1,960% +$521K ﹤0.01% 6483
2023
Q3
$21.7K Sell
738
-2,366
-76% -$112K ﹤0.01% 8296
2023
Q2
$197K Sell
3,104
-6,774
-69% -$375K ﹤0.01% 7685
2023
Q1
$466K Buy
+9,878
New +$528K ﹤0.01% 6437
2022
Q3
Sell
-653
Closed -$85K 10129
2022
Q2
$85K Sell
653
-691
-51% -$70.6K ﹤0.01% 8726
2022
Q1
$136K Sell
1,344
-3,103
-70% -$376K ﹤0.01% 9292
2021
Q4
$688K Buy
4,447
+3,449
+346% +$769K ﹤0.01% 6670
2021
Q3
$295K Buy
+998
New +$299K ﹤0.01% 8224

Other funds holding LYEL

Jane Street's LYEL Position: Q2 2026 in Review

Jane Street reduced its Lyell Immunopharma (LYEL) stake by 28% in Q2 2026, selling an estimated $324K and leaving 46,011 shares worth $646K. The position accounts for ﹤0.01% of the portfolio, ranked #7450.

Jane Street first reported a position in LYEL in Q3 2021 and has held it in 16 quarters since. The position peaked at $1.28M in Q1 2026. 87 funds tracked by Wall St. Rank hold LYEL as of Q2 2026.

  • Jane Street held 46,011 shares of Lyell Immunopharma worth $646K as of Q2 2026.
  • Jane Street sold 17,882 Lyell Immunopharma shares in Q2 2026, an estimated $324K.
  • Lyell Immunopharma made up ﹤0.01% of Jane Street's portfolio in Q2 2026, its #7450 holding.
  • Jane Street first reported a position in Lyell Immunopharma in Q3 2021 and has held it in 16 quarters since.
  • Jane Street's Lyell Immunopharma position peaked at $1.28M in Q1 2026.
  • 87 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.